Cancer type | Number | Study arms | Stage | Status | Design | Primary outcome | Estimated completion | Trial NCT |
---|---|---|---|---|---|---|---|---|
HCC | 35 | Nivolumab (anti PD-1 Ab) + LRT (Yttrium 90Y glass microspheres) | Phase 1 | Recruiting | Single Group Assignment | July 2019 | July 2019 | NCT02837029 |
HCC | 154 | PDR001 (anti PD-1 Ab) + NIS793 (anti TGF-b Ab) | Phase 1 | Recruiting | Non-Randomized | January 12, 2020 | January 12, 2020 | NCT02947165 |
HCC | 114 | Durvalumab (anti PD-1L Ab) + ramucirumab (anti-VEGF-R2 Ab) | Phase 1 | Recruiting | Non-Randomized | March 2018 | September 2018 | NCT02572687 |
HCC | 51 | Durvalumab (anti PD-1 L Ab) + AZD4635 | Phase 1 | Recruiting | Non-Randomized | November 9, 2017 | November 9, 2017 | NCT02740985 |
HCC | 61 | Tremelimumab (anti CTLA-4 Ab) | Phase 1 | Active, not recruiting | Non-Randomized | December 31, 2017 | December 31, 2018 | NCT01853618 |
Liver cancer | 60 | Ipilimumab (anti CTLA-4 Ab) + MGN1703 (Toll-like receptor agonist) | Phase 1 | Recruiting | Non-Randomized | May 2019 | May 2019 | NCT02668770 |
HCC | 120 | Ipilimumab (anti CTLA-4 Ab) + stereotactic body radiation | Phase 1 | Recruiting | Randomized | August 2019 | August 2019 | NCT02239900 |
HCC | 75 | Nivolumab (anti PD-1 Ab) + galunisertib (TGF-b inhibitor) | Phase 1/2 | Recruiting | Non-Randomized | April 2018 | March 2019 | NCT02423343 |
HCC | 620 | Nivolumab (anti PD-1 Ab) + ipilimumab (anti CTLA-4 Ab) | Phase 1/2 | Recruiting | Non-Randomized | July 22, 2018 | July 9, 2019 | NCT01658878 |
HCC | 108 | PDR001 (anti PD-1 Ab) + INC280 (c-Met inhibitor) | Phase 1/2 | Recruiting | Non-Randomized | December 24, 2018 | December 24, 2018 | NCT02795429 |
HCC | 50 | Prembrolizumab (anti PD-1 Ab) + dendritic cells, cytokine-induced killer cells | Phase 1/2 | Recruiting | Single Group Assignment | September 2019 | October 2019 | NCT02886897 |
HCC | 15 | Prembrolizumab (anti PD-1 Ab) | Phase 1/2 | Recruiting | Single Group Assignment | December 2019 | December 2019 | NCT02940496 |
HCC | 50 | Nivolumab (anti PD-1 Ab) + CC-122 (immunostimulatory pathway modifier) | Phase 1/2 | Recruiting | Single Group Assignment | June 23, 2020 | June 23, 2020 | NCT02859324 |
HCC | 90 | Durvalumab (anti PD-1 L Ab), Tremelimumab (anti CTLA-4 Ab) + LRT | Phase 1/2 | Recruiting | Non-Randomized | April 30, 2020 | April 30, 2021 | NCT02821754 |
HCC | 620 | Nivolumab (anti PD-1 Ab), Nivolumab + Ipilimumab, Nivolumab + cabozantinib, Nivolumab + Ipilimumab + cabozantinib | Phase 1/2 | Recruiting | Non- Randomized | September 4, 2018 | July 9, 2019 | NCT01658878 |
HCC | 28 | Pembrolizumab (Keytruda) (anti PD-1 Ab) | Phase 2 | Recruiting | Single Group Assignment | April 2018 | April 2019 | NCT02658019 |
HCC | 440 | Durvalumab (anti PD-1 L Ab) + Tremelimumab (anti CTLA-4 Ab) | Phase 2 | Recruiting | Randomized | March 20, 2020 | March 20, 2020 | NCT02519348 |
HCC | 726 | Nivolumab (anti PD-1 Ab) | Phase 3 | Recruiting | Randomized | October 1, 2018 | June 22, 2019 | NCT02576509 |
HCC | 408 | Prembrolizumab (anti PD-1 Ab) | Phase 3 | Active, not recruiting | Randomized | February 1, 2019 | February 1, 2019 | NCT02702401 |
HCC | 1200 | Durvalumab (anti PD-1 L Ab) + tremelimumab (anti CTLA-4 Ab) | Phase 3 | Not yet recruiting | Randomized | February 27, 2020 | March 29, 2021 | NCT03298451 |